Nasdaq
$3.86▲ 0.13%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $371.7MShares out 96.3M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
10- 1d agoAfter-hours26.10.24 05:524Ownership#●●●
Rezolute, Inc.
Daron Evans, an insider at Rezolute, Inc., filed a Form 4 statement of changes in beneficial ownership of securities on October 21, 2026. This filing serves as an official record of the insider's changes in equity holdings.…more
$3.86+0.13%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 3d agoAfter-hours26.10.22 05:47DEF 14AOther
Rezolute, Inc.
Rezolute, Inc. will hold its 2027 Annual Meeting of Stockholders on December 2, 2026, to vote on several proposals, including an amendment to increase the company's authorized common stock from 165 million to 225 million shares. The agenda also includes the election of directors, ratification of the independent auditor, and an advisory vote on executive compensation.…more
$3.86+0.13%vs prev closeView filingShare - 10.14After-hours26.10.15 06:118-KKey event
Rezolute, Inc.
Rezolute, Inc. has completed patient enrollment for its Phase 3 upLIFT study of ersodetug, a treatment candidate for tumor hyperinsulinism. The company expects to announce topline data from the 16-participant trial in mid-December 2026.…more
$3.86+0.13%vs prev closeView filingShare
9 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.14After-hours26.10.15 05:05#●●●#●●●#●●●
Rezolute Completes Enrollment for Phase 3 Tumor Hyperinsulinism Study
Rezolute has completed patient enrollment for its Phase 3 upLIFT study of ersodetug, with topline results expected in mid-December 2026. The company aims to advance this potential treatment for tumor-related hyperinsulinism pending favorable study outcomes.…more
$3.86+0.13%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 10.5Regular26.10.06 00:53
●●●●●●●● ●●●●● ●●●●●●
The FDA has recommended a pre-BLA meeting for Rezolute's rare disease drug despite the company failing to meet primary endpoints in its Phase 3 study. Regulators clarified that this recommendation does not guarantee final drug approval.…more
$3.86+0.13%vs prev closeShareBenzinga - 10.5Pre-market26.10.05 20:00
●●●●●●●● ●●●●● ●●●●●●
Despite failing to meet primary endpoints in its Phase 3 trial, the FDA has recommended a pre-BLA meeting to further evaluate the company's data. The FDA clarified that this recommendation does not guarantee approval, as a formal review process is still required.…more
$3.86+0.13%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report